Gupta M A, Gupta A K
Department of Psychiatry, University of Michigan Medical School, Ann Arbor 48109-0704, USA.
Cutis. 1995 Jul;56(1):53-4.
We present two patients with a history of chronic idiopathic urticaria occurring in conjunction with a panic disorder (DSM-IIIR), in whom both the urticaria and panic disorder responded favorably to a course of the selective serotonin reuptake inhibitor antidepressants fluoxetine and sertraline, respectively. Both patients had previously required systemic corticosteroids to manage their urticaria. Panic disorder is an anxiety disorder characterized by the presence of recurrent unexpected panic attacks. Serotoninergic mechanisms play an important role in panic disorder. In contrast to antidepressants such as doxepin, which have previously been found to be effective in the treatment of chronic urticaria, the newer selective serotonin reuptake inhibitor antidepressants are only weakly antihistaminic and anticholinergic. The response of both the urticaria and panic disorder to selective serotonin reuptake inhibitor antidepressants may suggest a common pathogenic factor involving serotoninergic mechanisms.
我们报告了两名患有慢性特发性荨麻疹并伴有惊恐障碍（DSM-IIIR）的患者，其中荨麻疹和惊恐障碍分别对选择性5-羟色胺再摄取抑制剂抗抑郁药氟西汀和舍曲林的一个疗程有良好反应。两名患者此前都需要全身性皮质类固醇来控制荨麻疹。惊恐障碍是一种焦虑症，其特征为反复出现意外的惊恐发作。5-羟色胺能机制在惊恐障碍中起重要作用。与先前发现对慢性荨麻疹治疗有效的抗抑郁药多塞平不同，新型选择性5-羟色胺再摄取抑制剂抗抑郁药仅有微弱的抗组胺和抗胆碱作用。荨麻疹和惊恐障碍对选择性5-羟色胺再摄取抑制剂抗抑郁药的反应可能提示涉及5-羟色胺能机制的共同致病因素。
